Biocon Biologics gains full gobal rights to biosimilar Adalimumab
Bengaluru: Biocon Biologics, a fully integrated global biosimilars company and subsidiary of Biocon, has announced that it has secured full and exclusive global rights for Hulio (biosimilar Adalimumab) from Fujifilm Kyowa Kirin Biologics(FKB).
Under this new agreement, Biocon Biologics will assume end-to-end responsibility for manufacturing and commercialization along with rights for any additional development activities.
The new agreement supersedes the existing collaboration agreement between Biocon Biologics and Fujifilm Kyowa Kirin Biologics for biosimilar Adalimumab, under which Biocon Biologics only had commercialization rights.
Under the terms of this agreement, Fujifilm Kyowa Kirin Biologics will participate in the development of the product and will offset certain development costs incurred by Biocon Biologics. In turn, Biocon Biologics will pay a technology license fee and royalties on sales to Fujifilm Kyowa Kirin Biologics for a specified tenure.
Commercial production of biosimilar Adalimumab at Biocon Biologics’ facilities will commence following successful technology transfer and regulatory approvals.
Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited, said, “This agreement with Fujifilm Kyowa Kirin Biologics provides Biocon Biologics the manufacturing rights to biosimilar Adalimumab, granting us end-to-end control over the product. This strategic move enhances flexibility and cost efficiency, reinforcing our commitment to expanding affordable access to high-quality biologics for patients with inflammatory diseases globally.”
Biocon Biologics initially acquired the commercial rights to biosimilar Adalimumab in 2022 through its acquisition of Viatris’ global biosimilars business. Viatris had previously in-licensed the product from Fujifilm Kyowa Kirin Biologics. Under the earlier arrangement, Fujifilm Kyowa Kirin Biologics manufactures and supplies the product to Biocon Biologics, which holds global commercial rights for HULIO.
Adalimumab is one of the three immunology biosimilars in Biocon Biologics’ overall portfolio.
Next Story